MedTrace Logo

Myfortic vs. Cellcept in Kidney Transplant Recipients

NCT00533624 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-09-28

No results posted yet for this study

Summary

The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal transplant recipients.

Conditions

Interventions

DRUG

Mycophenolate Sodium Delayed Release Tablets

Myfortic® 1,440 mg/day

DRUG

Mycophenolate Mofetil

Cellcept® 2,000 mg/day

Sponsors & Collaborators

Principal Investigators

  • George W Burke, M.D. · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533624 on ClinicalTrials.gov